Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00279448
Status:
COMPLETED
Last Update Posted:
2011-12-23
First Post:
2006-01-17
Brief Title:
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Multicenter Randomized Open-Label Study To Compare The Efficacy Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane Aromasin Therapy With 25 To 3 Years Of Adjuvant Tamoxifen Therapy Followed By 2 To 25 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR Post-Menopausal Patients With Non-Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEAM
Brief Summary:
To compare recurrence free survival between two treatment groups 5 years with exemestane vs 25 to 3 years tamoxifen followed by 2 to 25 years of exemestane for a total duration of 5 years
This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined A pre-specified analysis of the pooled data will be conducted Link to TEAM Trial 971-ONC-0028-081A5991026 Study Results httpclinicaltrialsgovct2showresultsNCT00036270term971-ONC-0028-081rank1
This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined A pre-specified analysis of the pooled data will be conducted Link to TEAM Trial 971-ONC-0028-081A5991026 Study Results httpclinicaltrialsgovct2showresultsNCT00036270term971-ONC-0028-081rank1
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A5991081 | None | None | None |